We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The FDA’s Endocrinologic and Metabolic Drugs Advisory Committee unanimously voted to expand the drug’s label last month after previously turning it down. Read More
The Association for Accessible Medicines said the changes “support open markets, greater competition and improved cost savings for patients.” Read More
Medtronic does not recommend prophylactic replacement of potentially affected pumps in patients because of the risks associated with replacement surgery. Read More